Publications | Page 4 | Jill Roberts Center for Inflammatory Bowel Disease

Jill Roberts Center for Inflammatory Bowel Disease

Found 123 results

Filters: Filter is [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

F

Longman RS, Littman DR. 2015. The functional impact of the intestinal microbiome on mucosal immunity and systemic autoimmunity.. Curr Opin Rheumatol. 27(4):381-7.

Cohen-Mekelburg S, Rosenblatt R, Gold S, Shen N, Fortune B, Waljee AK, Saini S, Scherl E, Burakoff R, Unruh M. 2019. Fragmented Care is Prevalent Among Inflammatory Bowel Disease Readmissions and is Associated With Worse Outcomes.. Am J Gastroenterol. 114(2):276-290.

Ahmed W, Lukin DJ. 2020. Finding a Needle in the Haystack? Defining the Role of Random Biopsies in IBD Dysplasia Surveillance. Inflamm Bowel Dis.

E

Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB et al.. 2013. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis.. Elife (Cambridge). 2:e01202.

Gogokhia L, Buhrke K, Bell R, Hoffman B, D Brown G, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF et al.. 2019. Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.. Cell Host Microbe. 25(2):285-299.e8.

DeFilippis EM, Tabani S, Warren RU, Christos PJ, Scherl EJ. 2016. Exercise and Self-Reported Limitations in Patients with Inflammatory Bowel Disease.. Dig Dis Sci. 61(1):215-20.

Dogan B, Belcher-Timme HFacey, Dogan EI, Jiang Z-D, Dupont HL, Snyder N, Yang S, Chandler B, Scherl EJ, Simpson KW. 2018. Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.. FEMS Microbiol Lett. 365(22)

Longman RS, Remotti H, Green PH. 2011. Esophagitis dissecans superficialis.. Gastrointest Endosc. 74(2):403-4.

Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H et al.. 2019. Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.. Inflamm Bowel Dis. 25(4):775-781.

Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel J-F, Lewis JD, Ghosh S et al.. 2020. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.. Gastroenterology. 158(8):2123-2138.e8.

Yang E, Panaccione N, Whitmire N, Dulai PS, Casteele NVande, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R et al.. 2020. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.. Aliment Pharmacol Ther. 51(11):1031-1038.

Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, Warren R, Trivellas M, Patel PV, Webb CD et al.. 2015. The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial.. Inflamm Bowel Dis. 21(12):2886-96.

Lima SF, Longman RS. 2021. Eating for Two: Diet and the Microbiome in Ulcerative Colitis.. J Crohns Colitis.

D

Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, Kamal K, Faye AS, Abrudescu P, Scherl E et al.. 2019. Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.. Aliment Pharmacol Ther. 49(5):564-571.

Lima S, Longman RS. 2021. A Diamond in the Rough: IgA-Seq Signatures Stratify New Onset IBD.. Cell Host Microbe. 29(1):10-12.

Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al.. 2021. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.

Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al.. 2020. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al.. 2018. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.

Longman RS, Braun D, Pellegrini S, Rice CM, Darnell RB, Albert ML. 2007. Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN-alpha/beta on antigen cross-presentation.. Blood. 109(3):1113-22.

Cohen-Mekelburg S, Gold S, Schneider Y, Dennis M, Oromendia C, Yeo H, Michelassi F, Scherl E, Steinlauf A. 2019. Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.. Dig Dis Sci. 64(1):196-203.

Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, Longman RS. 2020. Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis.. J Gastroenterol. 55(7):667-678.

Viladomiu M, Longman RS. 2021. Decoding the matrix: multiomics reveals host-microbe biomarker for inflammatory bowel disease.. J Clin Invest. 131(9)

C

Longman RS, Diehl GE, Victorio DA, Huh JR, Galan C, Miraldi ER, Swaminath A, Bonneau R, Scherl EJ, Littman DR. 2014. CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.. J Exp Med. 211(8):1571-83.

Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SGuk et al.. 2007. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum.. ISME J. 1(5):403-18.

Weinstock LB, Bosworth BP, Scherl EJ, Li E, Iroku U, Munsell MA, Mullen GE, Walters AS. 2010. Crohn's disease is associated with restless legs syndrome.. Inflamm Bowel Dis. 16(2):275-9.